What is Delestrogen injection used for?
Delestrogen injection (estradiol valerate) is a form of estrogen, a female hormone, used to treat symptoms of menopause such as hot flashes, and vaginal dryness, burning, and irritation.
Delestrogen injection is used to treat a lack of estrogen that is caused by ovarian failure or a condition called hypogonadism. Some forms of estradiol injection are used in men to treat the symptoms of prostate cancer.
What is the dosage of Delestrogen injection
The estradiol cypionate and estradiol valerate forms of long acting estrogen injection come as a liquid to inject into a muscle. These medications are usually injected by a health care professional once every 3 to 4 weeks. When the estradiol valerate form of estrogen injection is used to treat the symptoms of prostate cancer, it is usually injected by a health care professional once every 1 to 2 weeks.
The conjugated estrogens form of estrogen injection comes as a powder to mix with sterile water and inject into a muscle or vein. It is usually injected by a health care professional as a single dose. A second dose may be injected 6 to 12 hours after the first dose if it is needed to control vaginal bleeding.
If you are using Delestrogen injection to treat hot flushes, your symptoms should improve within 1 to 5 days after you receive the injection.
Which drugs or supplements interact with Delestrogen?
Delestrogen injection can inhibit the metabolism of cyclosporine, resulting in increased cyclosporine blood levels. Such increased blood levels can result in kidney and/or liver damage. If this combination cannot be avoided, cyclosporine concentrations can be monitored, and the dose of cyclosporine can be adjusted to assure that its blood levels are not elevated. We have
Estrogens appear to increase the risk of liver disease in patients receiving dantrolene through an unknown mechanism. Women over 35 years of age and those with a history of liver disease are especially at risk. Estrogens increase the liver’s ability to manufacture clotting factors. Because of this, patients receiving warfarin (Coumadin) need to be monitored for loss of anticoagulant (blood thinning) effect if an estrogen is added when warfarin is already being taken. Contact our support if you have questions